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SUMMARY
Pre-conditioning is an exciting physiological phenomenon that, despite great efforts, has so far resisted translation to mainstream clinical medicine. Many potential triggers (e.g., ischemia of the organ in question or a remote organ, many different drugs) have been investigated, but recent work has implicated activation of mitochondrial aldehyde dehydrogenase (ALDH2) as central to the process. A genetic polymorphism, known as ALDH2*2, is common worldwide (present in up to 40% of Han Chinese people) and produces a functionally in recent years (1) (2) (3) . Nitrite may have a role in hypoxic vasodilation (4) and has been shown to protect renal tissue (5, 6) , liver (7) , and myocardium (8, 9) from ischemia-reperfusion (IR) injury in animal models. Nitrate (NO 3 À ), administered orally in beetroot juice, protected endothelium from IR injury in healthy human volunteers (9) , an effect attributed to a 2-fold increase in plasma nitrite. Mitochondrial aldehyde dehydrogenase (ALDH2) is a member of the 19-strong human aldehyde dehydrogenase family of NAD(P) þ -dependent enzymes (12) . A common polymorphism in exon 12 (Glu487Lys, or Glu504Lys in the unspliced protein), known as the ALDH2*2 allele, is present in up to 50% of individuals of East Asian descent (13) . Heterozygosity at this allele results in a near inactive enzyme and produces the "Asian Flushing" phenotype, a phenomenon linked to the accumulation of acetaldehyde following alcohol ingestion; mutation of a single subunit destabilizes the cofactor binding site and dimer interface such that heterozygotes are functionally similar to homozygotes with the variant allele (14) . Individuals possessing 1 or 2 copies of the ALDH2*2
allele may be at greater risk of coronary artery disease (15) and myocardial infarction (16) . ALDH2 activation by phosphorylation has been postulated to be central to protection conferred against myocardial ischemia reperfusion injury (17) . Pre-conditioning was induced by activation of PKCε (which phosphorylates ALDH2) and subsequently by a direct activator of ALDH2, alda-1. In a later study, the volatile anesthetic isoflurane induced cardioprotection in a rat model (18) .
Protection was associated with activation of ALDH2
and was abolished by an inhibitor of PKCε. On the basis of these data, combined with the observation that ALDH2 also exhibits intrinsic nitrite reductase activity (19) , we hypothesized that an interaction between ALDH2 and nitrite might contribute to IR protection in humans.
We hypothesized that nitrite would be protective in the human forearm, either when administered 24 h before ischemia reperfusion ("second-window preconditioning") or when administered during ischemia (with the primary effect in the "post-conditioning" window), and that its protective effects would be modified by variations in ALDH2 activity. We used a combination of genetic and pharmacological tools in an established model of IR injury in the human forearm (20) , to investigate protection by nitrite and the role of ALDH2.
METHODS
This study was approved by the local research ethics committee. All participants gave written informed consent. All studies were performed in a dedicated vascular laboratory, maintained at 22 C to 24 C in quiet conditions. All participants were nonsmokers, and none was on medications of any kind. The baseline characteristics are given in Table 1 . All participants avoided nitrite/nitrate-rich foods or alcohol for 24 h before the study, and abstained from caffeine on the day of the study. There was a washout period of >1 week between runs in the same patient. (20) . The study design is summarized in Figure 1A . Values are mean AE SD or n.
ALDH2 ¼ mitochondrial aldehyde dehydrogenase; BMI ¼ body mass index; HR ¼ heart rate; MABP ¼ mean arterial blood pressure. there was a washout period of >1 week between any given studies in the same BLOOD SAMPLING. Venous blood samples were taken before ischemia and then after 1 min of reperfusion. Samples were placed in tubes spiked with EDTA (10 mmol/l) and NEM (2 mmol/l), transferred on ice to a chilled (4 C) centrifuge, and then spun at 4,000 rpm for 15 min. Plasma samples were then snap frozen in liquid nitrogen and stored at À80 C. Plasma nitrate/nitrite (NO x ) and nitrosylated species (RXNO) levels were measured using gas-phase chemiluminescence (21) .
DETERMINATION OF ALDH2 GENOTYPE. Participants were not asked at any stage and were discouraged from discussing whether they possessed any features of the "flushing" phenotype in order to preserve blinding. Genetic analysis for ALDH2 genotype was performed for all participants after the completion of studies, in order to maintain blinding. DNA was extracted from venous blood samples (QIAamp, Qiagen, Hilden, Germany) and analyzed using commercial probes and primers (Taqman System, Applied Biosciences, Thermo Fisher Scientific, Waltham, Massachusetts). One participant was found to be homozygous at the *2 allele. This dataset was excluded from the analysis.
ALDH2-DEPENDENT INACTIVATION BY NITRITE.
Expression and purification of ALDH2 was performed as previously described (22) . Dehydrogenase activity was measured by monitoring the formation of NADH as an increase in light absorbance at 340 nm in 50 mmol/l sodium pyrophosphate buffer (pH 7.5) containing 0.4 mmol/l acetaldehyde, 10 mmol/l MgCl 2 , and 5 mmol/l NAD. After 2 min of equilibration, the reactions were started by the addition of ALDH2*1 or ALDH2*2 (19 and 111 mg/ml final concentrations, respectively) and monitored for w3 min to obtain initial reaction rates. Activities were subsequently measured after the addition of 10 mmol/l NaNO 2 and 1 mmol/l dithiothreitol.
TREATMENT PROTOCOLS. Treatment protocols are summarized in Figure 1B . Ormerod et al.
given in Table 1 . All Caucasian participants were homozygous for the wild-type ALDH2 (ALDH2*1/*1)
allele. Of the East Asian participants, 11 were homozygous for wild-type ALDH2 (ALDH2*1/*1) and 11 were heterozygotes (ALDH2*1/*2). One was homozygous for the variant ALDH2 (ALDH2*2/*2) and was excluded from the analysis. The IR protocol did not affect heart rate or blood pressure in any group; resting heart rate and blood pressure were similar on each study day (data not shown). Changes in endothelium-independent FBF were similar between groups (data not shown).
Twenty minutes of forearm ischemia induced significant endothelial dysfunction in individuals with (p < 0.0001, n ¼ 9) or without (p ¼ 0.0001, n ¼ 9)
the ALDH2*2 allele ( Figures 3A and 3B ).
Plasma nitrite levels at baseline were similar in those with and without the ALDH2*2 allele. During studies where nitrite was administered, plasma nitrite increased from 1.43 AE 0.12 mmol/l to 3.39 AE 1.23 mmol/l in individuals with the *1 wild-type variant (p < 0.05, n ¼ 8) but only from 1.33 AE 0.12 mmol/l to 2.56 AE 1.42 mmol/l in those with the *2 variant ( Figure 4A) . The plasma nitrate and RXNO were not significantly different at baseline and were not significantly different at 1 min of reperfusion (data not shown).
Sodium nitrite mildly inhibited ALDH2*1 (by 6.4%; p ¼ 0.04, n ¼ 3), whereas ALDH2*2 was neither stimulated nor inhibited by nitrite ( Figure 4B) . The *2 variant enzyme exhibited a rightward shift in the soluble guanylate cyclase stimulation curve (a surrogate of NO generation) at moderate levels of nitrite ( Figure 4C) .
One mg/kg/min sodium nitrite administered intravenously during the latter 10 min of ischemia prevented endothelial dysfunction in participants that were heterozygous for the ALDH2*2 allele (p ¼ 0.63, n ¼ 8) ( Figure 3C) . Homozygous wild-type individuals did not display protection (p ¼ 0.006, n ¼ 10) ( Figure 3D ). pre-treated with disulfiram and administered 1 mg/kg/min sodium nitrite intravenously during the latter 10 min of ischemia displayed significant postischemic endothelial dysfunction (p < 0.0001, n ¼ 6), suggesting no protective effect of nitrite in this setting ( Figure 5 ). The NIAMI study in acute ST-segment elevation myocardial infarction was also negative (11) . Our results in those homozygous for wild-type ALDH2*1 are consistent with these previous studies in demonstrating no reduction in ischemia reperfusion injury when nitrite is administered during ischemia. al. [8] ). However, the protective effect seen in those with the variant enzyme, who appear to have a smaller rise in plasma nitrite, may suggest that in the post-conditioning phase, this dose is too high. It has been reported that very high levels of NO may prevent protection (24) . Thus, it is possible that, in the post-ischemia phase, the kinetics of nitrite metabolism are altered such that this dose is not protective. However, our inability to restore protection by pharmacological inhibition suggests that this enzyme system alone is not responsible for these effects.
DISCUSSION
Although we cannot exclude off-target effects of disulfiram contributing to this observation, we believe that the interaction between nitrite and the ALDH2*1/*2 genotype is more nuanced than nitrite simply augmenting the detoxifying potential of an enzyme with reduced dehydrogenase activity (e.g., with respect to reactive aldehydes such as 4-hydroxy- (25) ; however, the relevance of this mechanism in humans is unclear.
Because the study involves puncture of the brachial artery, it was felt that it was not reasonable to require more than 2 runs from each participant.
Ideally, the effect of disulfiram and delayed protection would have been studied in the East Asian population, but insufficient participants were recruited.
It was not possible to analyze as a crossover study, because not all participants completed both arms of the study. The data from placebo and nitrite runs were analyzed separately in the same manner as previously discussed (20, 26) . There was a washout period of at least 1 week between studies that we believe was sufficient to preclude ongoing effects, and the placebo and nitrite studies were performed in random order. However, we cannot absolutely exclude effects of the previous study, and hence, we list this as a limitation. Finally, our disulfiram group consisted of men only, although there were no significant effects of sex found in any of the other groups. The biochemical study of ALDH2 inhibition/ however, the negative NIAMI study (11) has somewhat reduced enthusiasm for further trials of exogenous nitrite in ischemia. More recent work has focused on a potential role of endogenous nitrite in cytoprotection, for example as a mediator of remote ischemic pre-conditioning (28) . In a mouse model of myocardial infarction, this study confirmed the role of nitrite by use of a nitrite scavenger to abolish the effect of RIPC, and then recapitulated this protection with nitrite-supplemented plasma. In their editorial accompanying this study, Corti and Gladwin (29) argued that reliance on animal models may be limiting our ability to translate this undoubtedly exciting physiological process to mainstream medicine. Equally, human ischemic models (such as the one used here) may not translate to other tissues or organs, or to pathological states, though they may well provide insight into the mechanisms involved.
It is generally agreed that cytoprotection proceeds down a final common pathway (30), so it seems likely that protection by nitrite seen in the forearm may be achieved in other tissues under the correct conditions. However, as Corti and Gladwin (29) argue, multiple factors-the nitrite dose, the plasma levels achieved, and the timing of interventioncreate a complex system and are all critical to the successful translation of cytoprotection to human patients. 
CONCLUSIONS

